Melior Discovery, Inc.
Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA, that specializes in the field of drug repositioning, also widely known as drug repurposing. Founded in 2005, the company has established itself as a pioneer in in vivo phenotypic screening and a key provider of preclinical pharmacology services to the global pharmaceutical and biopharmaceutical industry. Its business model is structured to drive near-term revenue-generating activities through its discovery services while simultaneously investing in longer-term pipeline value creation.
Continue…Core Business and Strategic Focus
The fundamental activity of Melior Discovery is the identification of new therapeutic uses (indications) for existing drug candidates that have already been developed for a different purpose or have stalled in their original development pathway. This process of drug repositioning is highly valuable as it significantly de-risks the drug development process by starting with compounds for which a substantial amount of clinical safety, pharmacokinetic, and toxicology data may already exist.
Melior???s approach is centered around in vivo phenotypic screening. This method involves testing drug candidates systematically against a wide variety of whole-animal disease models rather than focusing on a single molecular target. This unbiased, empirical method is designed to rapidly and cost-effectively identify unexpected therapeutic potential for compounds.
Proprietary Technology and Platform
The cornerstone of Melior Discovery???s services and internal pipeline generation is its proprietary theraTRACE(R) platform.
- Systematic Screening: The theraTRACE(R) platform enables the systematic screening of chemical compounds across a diverse array of validated in vivo disease models. This comprehensive evaluation helps to uncover novel biological activities and new indications for existing drug candidates.
- Disease Model Library: The company has developed a vast and continuously validated library of animal models, comprising over 80 (and potentially over 150, according to some reports) distinct models of human disease. These models span a wide range of therapeutic areas, providing broad coverage for potential drug efficacy.
- Therapeutic Areas: The disease models available through the platform cover a broad spectrum of medical conditions, including inflammation, immunology, diabetes and metabolic syndrome, dermatology, cardiovascular diseases, gastrointestinal disorders, and various psychiatric, neurological, and neurodegenerative disorders.
Products and Services Offered
Melior Discovery operates as both a drug discovery company and a Contract Research Organization (CRO), providing specialized services to external clients and supporting its internal drug development pipeline.
1. Contract Research Organization (CRO) Services
Melior is a world-class provider of specialized in vivo pharmacology services for the global pharmaceutical and biopharmaceutical industry. These services are critical for clients in need of preclinical efficacy data for their candidate therapeutics.
- In Vivo Efficacy Testing: The primary service involves evaluating drug candidates in their comprehensive catalog of validated animal models of human disease.
- Custom Model Development: In addition to its extensive catalog, Melior offers services for the development of custom disease models, modifications to existing models, and assistance in replicating models from scientific literature.
- Preclinical Support: The company provides state-of-the-art preclinical pharmacology support, including running series of in vivo studies on a frequent, often weekly, basis to accelerate preclinical drug development programs and allow for quicker adjustments to compound design.
The quality and expertise in their in vivo pharmacology services have led to long-standing recognition and partnerships with major pharmaceutical entities.
2. Internal Drug Discovery and Repositioning
Using the proprietary theraTRACE(R) platform, Melior Discovery identifies and validates its own drug candidates for new indications.
- Pipeline Generation: Qualified and progressed drug candidates that emerge from the screening process are then typically spun off to an affiliate company, Melior Pharmaceuticals, for further clinical development and commercialization.
- Lead Candidate Example: A notable product of Melior???s discovery efforts is MLR-1023, an Investigational New Drug (IND) for the treatment of type 2 diabetes. The company received FDA approval for its IND application for this therapeutic candidate in March 2009 and subsequently reported positive results from its Phase 2a clinical study in diabetic subjects in June 2016. This candidate was eventually licensed to Bukwang Pharmaceutical Company LTD for further clinical trials.
3. Strategic Collaborations and Partnerships
Melior Discovery???s drug repositioning technology has been cited as the basis for numerous high-profile corporate partnerships. The company has successfully executed collaboration agreements with several of the world???s largest pharmaceutical companies, including:
- Pfizer
- Merck & Co.
- Johnson & Johnson
- AstraZeneca
These partnerships highlight the recognized value of Melior???s unique phenotypic screening and drug repositioning capabilities in reducing the risk and cost associated with early-stage drug discovery.
